Table 2 Distribution of type 1 macular neovascularization exudative features according to Naïve and switch status
Exudative feature | Follow-up visit | Type 1 MNV | Total (%) | P-value | |
|---|---|---|---|---|---|
Switch (n = 52) | Naïve (n = 13) | ||||
N (%) | N (%) | ||||
SRF | Baseline | 40 (76.9) | 12 (92.3) | 52 (80.0) | 0.214 |
3-month | 14 (26.9) | 3 (23.1) | 17(26.1) | 0.777 | |
6-month | 17 (32.7) | 2 (15.4) | 19 (29.2) | 0.219 | |
12-month | 6 (11.5) | 0 (0.0) | 6 (9.2) | 0.198 | |
IRF | Baseline | 15 (28.8) | 2 (15.3) | 17 (26.1) | 0.323 |
3-month | 5 (9.6) | 0 (0.0) | 5 (7.7) | 0.244 | |
6-month | 7 (13.7) | 0 (0.0) | 7 (10.8) | 0.161 | |
12-month | 5 (9.6) | 0 (0.0) | 5 (7.6) | 0.245 | |
SHRM | Baseline | 4 (7.6) | 5 (38.4) | 9 (13.8) | 0.004* |
3-month | 3 (5.8) | 0 (0.0) | 3 (4.6) | 0.375 | |
6-month | 4 (7.7) | 0 (0.0) | 4 (6.1) | 0.296 | |
12-month | 3 (5.8) | 0 (0.0) | 3 (4.6) | 0.373 | |
Outward Exudation | Baseline | 7 (13.4) | 1 (7.6) | 8 (15.4) | 0.571 |
3-month | 5 (9.6) | 1 (7.7) | 6 (9.2) | 0.832 | |
6-month | 3 (5.8) | 1 (7.7) | 4 (6.1) | 0.795 | |
12-month | 3 (5.8) | 0 (0.0) | 3 (4.6) | 0.373 | |